• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

金泌通软性亲水硅胶引流植入物的中期疗效观察

Intermediate-term outcome of Aurolab aqueous drainage implant.

机构信息

Department of Glaucoma, Aravind Eye Hospital, Coimbatore, Tamil Nadu, India.

出版信息

Indian J Ophthalmol. 2019 Feb;67(2):233-238. doi: 10.4103/ijo.IJO_675_18.

DOI:10.4103/ijo.IJO_675_18
PMID:30672476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6376828/
Abstract

PURPOSE

To report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma.

METHODS

Retrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months were included. Success was defined as complete when the intraocular pressure was ≥6 and ≤21 mmHg without antiglaucoma medication and as qualified if those requiring additional antiglaucoma medications were included.

RESULTS

The study included 55 patients (55 eyes) with a mean age ± standard deviation (SD) of 47.3 ± 18.1 years with a mean follow-up of 16.7 ± 11.4 months. Mean intraocular pressure reduced from 30.8 ± 11.1 mmHg to 13.1 ± 4.7, 14.1 ± 4.8, 15.7 ± 2.5 (P < 0.001) mmHg at 6 months, 1 year, and 2 years, respectively. The mean number of antiglaucoma medications reduced from 3.4 ± 1 to 0.8 ± 1.2, 0.7 ± 1.1, 0.8 ± 1 (P < 0.001) at 6 months, 1 year, and 2 years, respectively. The cumulative probability of complete and qualified success was 62% and 100% at 6 months, 54% and 92% at 1 year, and 43% and 88% at 2 years, respectively. Four patients failed during the follow-up period. Postoperative complication occurred in 28 eyes (51%), of which 17 eyes (31%) required intervention.

CONCLUSION

AADI is a safe and effective treatment for the control of intraocular pressure in patients with glaucoma.

摘要

目的

报告青光眼患者使用 Aurolab 水凝胶引流植入物（AADI）的中期安全性和疗效。

方法

回顾性分析 2013 年 1 月至 2016 年 12 月期间接受 AADI 的患者。纳入年龄>16 岁且随访时间至少 6 个月的患者。将完全成功定义为眼压≥6mmHg 且≤21mmHg 且无需抗青光眼药物，将合格定义为包括需要额外抗青光眼药物的患者。

结果

本研究纳入了 55 例（55 只眼）患者，平均年龄±标准差（SD）为 47.3±18.1 岁，平均随访时间为 16.7±11.4 个月。平均眼压从 30.8±11.1mmHg 分别降至 6 个月、1 年和 2 年时的 13.1±4.7mmHg、14.1±4.8mmHg 和 15.7±2.5mmHg（P<0.001）。平均抗青光眼药物数量从 3.4±1 降至 6 个月、1 年和 2 年时的 0.8±1.2、0.7±1.1 和 0.8±1（P<0.001）。6 个月、1 年和 2 年时完全成功和合格成功的累积概率分别为 62%和 100%、54%和 92%以及 43%和 88%。在随访期间有 4 例患者失败。28 只眼（51%）发生术后并发症，其中 17 只眼（31%）需要干预。

结论

AADI 是一种安全有效的治疗方法，可控制青光眼患者的眼压。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/7ef412d124d3/IJO-67-233-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/b87b54da0146/IJO-67-233-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/3a86295d96e9/IJO-67-233-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/d991a053151d/IJO-67-233-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/7ef412d124d3/IJO-67-233-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/b87b54da0146/IJO-67-233-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/3a86295d96e9/IJO-67-233-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/d991a053151d/IJO-67-233-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/6376828/7ef412d124d3/IJO-67-233-g004.jpg

相似文献

1
Intermediate-term outcome of Aurolab aqueous drainage implant.金泌通软性亲水硅胶引流植入物的中期疗效观察
Indian J Ophthalmol. 2019 Feb;67(2):233-238. doi: 10.4103/ijo.IJO_675_18.
2
A prospective randomized controlled study of Aurolab aqueous drainage implant versus Ahmed glaucoma valve in refractory glaucoma: A pilot study.前瞻性随机对照研究 Aurolab 水性引流植入物与 Ahmed 青光眼阀治疗难治性青光眼：一项初步研究。
Indian J Ophthalmol. 2018 Nov;66(11):1580-1585. doi: 10.4103/ijo.IJO_427_18.
3
Long-term outcome of low-cost glaucoma drainage device (Aurolab aqueous drainage implant) compared with Ahmed glaucoma valve.廉价青光眼引流装置（Aurolab 水引流植入物）与 Ahmed 青光眼阀的长期疗效比较。
Br J Ophthalmol. 2020 Apr;104(4):557-562. doi: 10.1136/bjophthalmol-2019-313942. Epub 2019 Jul 4.
4
Comparison of Short-term Outcomes of Aurolab Aqueous Drainage Implant with Ahmed Glaucoma Valve in Post-Penetrating Keratoplasty Glaucoma: A Retrospective Follow-up Study at a Tertiary Care Center.穿透性角膜移植术后青光眼采用 Aurolab 水引流植入物与 Ahmed 青光眼阀的短期疗效比较：三级护理中心的回顾性随访研究。
Ophthalmol Glaucoma. 2019 May-Jun;2(3):172-177. doi: 10.1016/j.ogla.2019.02.005. Epub 2019 Feb 12.
5
Comparison of the New Low-Cost Nonvalved Glaucoma Drainage Device with Ahmed Glaucoma Valve in Refractory Pediatric Glaucoma in Indian Eyes.新型低成本无阀青光眼引流装置与 Ahmed 青光眼阀在印度人儿童难治性青光眼的比较。
Ophthalmol Glaucoma. 2018 Nov-Dec;1(3):167-174. doi: 10.1016/j.ogla.2018.07.001. Epub 2018 Aug 17.
6
A preliminary comparison of the Aravind aurolab drainage implant with the Baerveldt glaucoma implant: A matched case-control study.阿伐林德拉夫（Aravind）前房引流植入物与巴伐利特（Baerveldt）青光眼植入物的初步比较：一项匹配的病例对照研究。
Eur J Ophthalmol. 2021 Mar;31(2):445-452. doi: 10.1177/1120672120912383. Epub 2020 Mar 18.
7
Two-Year Outcomes of the New Low-cost Nonvalved Aurolab Aqueous Drainage Implant in Refractory Glaucoma.新型低成本非瓣膜性 Aurolab 水引流植入物治疗难治性青光眼的两年疗效。
J Glaucoma. 2020 Sep;29(9):767-772. doi: 10.1097/IJG.0000000000001532.
8
Intermediate-Term Outcomes of an Affordable Aqueous Drainage Implant in Adults with Refractory Glaucoma.成人难治性青光眼廉价水引流植入物的中期结果。
Ophthalmol Glaucoma. 2019 Jul-Aug;2(4):258-266. doi: 10.1016/j.ogla.2019.03.009. Epub 2019 Apr 4.
9
Intermediate-term outcomes of pars plana tube insertion of Aurolab aqueous drainage implant for refractory glaucoma.经睫状体平坦部巩膜隧道切口植入 Aurolab 房水引流植入物治疗难治性青光眼的中期疗效。
Br J Ophthalmol. 2020 Sep;104(9):1293-1297. doi: 10.1136/bjophthalmol-2019-314639. Epub 2019 Dec 3.
10
Intermediate-term outcomes of Aurolab aqueous drainage implant in refractory paediatric glaucoma.水凝胶引流植入物治疗难治性儿童青光眼的中期疗效。
Br J Ophthalmol. 2020 Jul;104(7):962-966. doi: 10.1136/bjophthalmol-2019-314399. Epub 2019 Oct 4.

引用本文的文献

1
The long-term surgical outcomes of the Aurolab aqueous drainage implant versus the Ahmed glaucoma valve for refractory pediatric glaucoma in Saudi children.沙特儿童难治性小儿青光眼采用Aurolab房水引流植入物与艾哈迈德青光眼阀的长期手术效果比较
Indian J Ophthalmol. 2025 Mar 1;73(Suppl 2):S293-S297. doi: 10.4103/IJO.IJO_1370_24. Epub 2025 Feb 21.
2
Efficacy and Safety of Aurolab Aqueous Drainage Implant Compared With Baerveldt Glaucoma Implant for Refractory Glaucoma at One Year: A Systematic Review and Meta-Analysis.与Baerveldt青光眼植入物相比，Aurolab水性引流植入物治疗难治性青光眼一年的疗效和安全性：一项系统评价和荟萃分析。
J Ophthalmol. 2024 Nov 1;2024:8617959. doi: 10.1155/2024/8617959. eCollection 2024.
3

本文引用的文献

1
Surgical Outcomes of a New Low-Cost Nonvalved Glaucoma Drainage Device in Refractory Glaucoma: Results at 1 Year.新型低成本无阀青光眼引流装置治疗难治性青光眼的手术效果：1 年随访结果。
J Glaucoma. 2018 May;27(5):433-439. doi: 10.1097/IJG.0000000000000930.
2
Safety and efficacy of a low-cost glaucoma drainage device for refractory childhood glaucoma.一种用于难治性儿童青光眼的低成本青光眼引流装置的安全性和有效性。
Br J Ophthalmol. 2017 Dec;101(12):1623-1627. doi: 10.1136/bjophthalmol-2017-310276. Epub 2017 May 6.
3
The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes.
Intermediate-term outcome of Aurolab aqueous drainage implant in refractory glaucoma.
Aurolab房水引流植入物治疗难治性青光眼的中期结果
Saudi J Ophthalmol. 2023 Oct 24;37(4):321-326. doi: 10.4103/sjopt.sjopt_117_22. eCollection 2023 Oct-Dec.
4
Incidence, outcomes, and risk of surgical failure after development of early hypotony following Aurolab aqueous drainage implant surgery.奥洛拉水凝胶引流植入术后早期低眼压发展后手术失败的发生率、结局和风险。
Indian J Ophthalmol. 2023 Feb;71(2):586-593. doi: 10.4103/ijo.IJO_2076_22.
5
Commentary: Aurolab aqueous drainage implant: Miles to go.评论：奥罗实验室房水引流植入物：仍需努力。
Indian J Ophthalmol. 2022 Dec;70(12):4216-4217. doi: 10.4103/ijo.IJO_2226_22.
6
Safety and efficacy of Aurolab aqueous drainage implant in refractory glaucoma: A prospective study.奥罗拉水性引流植入物治疗难治性青光眼的安全性和有效性：一项前瞻性研究。
Indian J Ophthalmol. 2022 Dec;70(12):4212-4216. doi: 10.4103/ijo.IJO_1391_22.
7
Honeycomb epithelial oedema due to ripasudil: clinical, optical coherence tomography and histopathological correlation.利匹司特引起的巢状上皮水肿：临床、光学相干断层扫描和组织病理学相关性。
BMJ Case Rep. 2022 Jul 26;15(7):e251074. doi: 10.1136/bcr-2022-251074.
8
Retinal detachment in eyes treated with Aurolab aqueous drainage implant for refractory glaucoma - Incidence and outcomes.治疗难治性青光眼的 Aurolab 水引流植入术后的视网膜脱离 - 发生率和结果。
Indian J Ophthalmol. 2022 Apr;70(4):1287-1293. doi: 10.4103/ijo.IJO_1546_21.
9
Commentary: Placement of the tube of a glaucoma drainage device: Different horses for different courses.评论：青光眼引流装置引流管的放置：因材施教。
Indian J Ophthalmol. 2022 Mar;70(3):845-846. doi: 10.4103/ijo.IJO_2877_21.
10
Pars plana Aurolab aqueous drainage implantation for refractory glaucoma: Outcome of a new modified technique.经睫状体平坦部巩膜造瘘房水引流植入术治疗难治性青光眼：一种新改良技术的结果。
Indian J Ophthalmol. 2022 Mar;70(3):839-845. doi: 10.4103/ijo.IJO_1791_21.
艾哈迈德对 Baerveldt 研究：五年治疗结果。
Ophthalmology. 2016 Oct;123(10):2093-102. doi: 10.1016/j.ophtha.2016.06.035. Epub 2016 Aug 17.
4
Five-year treatment outcomes in the Ahmed Baerveldt comparison study.艾哈迈德·贝尔费尔特比较研究中的五年治疗结果。
Ophthalmology. 2015 Feb;122(2):308-16. doi: 10.1016/j.ophtha.2014.08.043. Epub 2014 Oct 17.
5
The Ahmed Versus Baerveldt study: one-year treatment outcomes.艾哈迈德对贝弗利特研究：一年治疗结果。
Ophthalmology. 2011 Nov;118(11):2180-9. doi: 10.1016/j.ophtha.2011.05.004. Epub 2011 Sep 1.
6
Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up.艾哈迈德·巴伐尔特（Ahmed Baerveldt）比较研究的 1 年随访后治疗结果。
Ophthalmology. 2011 Mar;118(3):443-52. doi: 10.1016/j.ophtha.2010.07.016. Epub 2010 Oct 8.
7
Prevalence and risk factors for primary glaucomas in adult urban and rural populations in the Andhra Pradesh Eye Disease Study.安得拉邦眼病研究中成年城乡居民原发性青光眼的患病率及危险因素。
Ophthalmology. 2010 Jul;117(7):1352-9. doi: 10.1016/j.ophtha.2009.11.006. Epub 2010 Feb 25.
8
Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up.在随访一年后，管状手术与小梁切除术研究中的治疗结果。
Am J Ophthalmol. 2007 Jan;143(1):9-22. doi: 10.1016/j.ajo.2006.07.020. Epub 2006 Sep 1.
9
Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up.在“导管与小梁切除术研究”中随访第一年的手术并发症。
Am J Ophthalmol. 2007 Jan;143(1):23-31. doi: 10.1016/j.ajo.2006.07.022. Epub 2006 Sep 1.
10
The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome.用于难治性青光眼的艾哈迈德分流器与贝尔维尔德分流器：单术者的疗效比较
Ophthalmology. 2003 Sep;110(9):1814-21. doi: 10.1016/S0161-6420(03)00574-8.